The population-level costs of immunosuppression medications for the treatment of glomerulonephritis are increasing over time due to changing patterns of practice-Reference-Cited by-同舟云学术

The population-level costs of immunosuppression medications for the treatment of glomerulonephritis are increasing over time due to changing patterns of practice

Published:2017-07-02 Issue:4 Volume:33 Page:626-634
ISSN:0931-0509
Container-title:Nephrology Dialysis Transplantation
language:en
Short-container-title:

Author:

Barbour Sean¹²³,Lo Clifford¹,Espino-Hernandez Gabriela¹,Sajjadi Sharareh⁴,Feehally John⁵,Klarenbach Scott⁶,Gill Jagbir¹²³

Affiliation:

1. Department of Medicine, BC Provincial Renal Agency, Vancouver, BC, Canada

2. Division of Nephrology, University of British Columbia, Vancouver, BC, Canada

3. Centre for Health Evaluation and Outcomes Research, St Paul’s Hospital, Vancouver, BC, Canada

4. Department of Medicine, University of British Columbia, Vancouver, BC, Canada

5. Department of Medicine, The John Walls Renal Unit, Leicester General Hospital, Leicester, UK

6. Department of Medicine, University of Alberta, Edmonton, AB, Canada

Publisher

Oxford University Press (OUP)

Subject

Transplantation,Nephrology

Link

http://academic.oup.com/ndt/article-pdf/33/4/626/24524967/gfx185.pdf

Reference45 articles.

1. KDIGO clinical practice guidelines for glomerulonephritis;Group KDIGOKGW;Kidney Int,2012

2. Healthcare cost and loss of productivity in a Canadian population of patients with and without lupus nephritis;Aghdassi;J Rheumatol,2011

3. A structured literature review of the direct costs of adult systemic lupus erythematosus in the US;Slawsky;Arthritis Care Res,2011

4. The cost of care of systemic lupus erythematosus (SLE) in the UK: annual direct costs for adult SLE patients with active autoantibody-positive disease;Khamashta;Lupus,2014

5. Ten common mistakes in the management of lupus nephritis;Bose;Am J Kidney Dis,2014

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review on epidemiology, disease burden, and treatment patterns of IgA nephropathy in select APAC countries;BMC Nephrology;2024-04-16

2. Prevalence, Resource Utilization and Economic Impact of Kidney Function and Proteinuria in Patients with Focal Segmental Glomerulosclerosis;2024-02-13

3. Comparative pharmacoeconomic analysis of rituximab and traditional tacrolimus regimens in membranous nephropathy in China;Frontiers in Pharmacology;2024-01-08

4. Impact of Proteinuria and Kidney Function Decline on Health Care Costs and Resource Utilization in Adults With IgA Nephropathy in the United States: A Retrospective Analysis;Kidney Medicine;2023-09

5. Humanistic and Economic Burden of IgA Nephropathy: Systematic Literature Reviews and Narrative Synthesis;PharmacoEconomics - Open;2023-04-27